Michael Celano's Net Worth
$2.53 Million
Who is Michael Celano?
Michael Celano has an estimated net worth of $2.53 Million. This is based on reported shares across multiple companies, which include ORASURE TECHNOLOGIES INC, Larimar Therapeutics, Inc., Recro Pharma, Inc., and KENSEY NASH CORP.
SEC CIK
Michael Celano's CIK is 0001377582
Past Insider Trading and Trends
2019 was Michael Celano's most active year for acquiring shares with 7 total transactions. Michael Celano's most active month to acquire stocks was the month of December. 2017 was Michael Celano's most active year for disposing of shares, totalling 8 transactions. Michael Celano's most active month to dispose stocks was the month of December. 2020 saw Michael Celano paying a total of $130,003.00 for 152,722 shares, this is the most they've acquired in one year. In 2017 Michael Celano cashed out on 120,151 shares for a total of $1,151,381.81, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ORASURE TECHNOLOGIES INC (OSUR) Snapshot price: $4.1129
Director
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +12.02% | 12K |
$4.49 | $53,916.00 | 111.82K |
Aug 12
| |||
Form 4
| +27.23% | 21.36K |
$5.25 | $112,155.75 | 99.82K |
May 16
| |||
Form 4
| +17.21% | 11.52K |
$9.55 | $110,604.96 | 78.46K |
May 17 - May 18
| |||
Form 4
| +6.86% | 4.3K |
$16.01 | $68,360.90 | 66.94K |
May 15 - May 18
| |||
Form 4
| +32.40% | 15.33K |
$8.48 | $129,998.40 | 62.64K |
May 21
| |||
Form 4
| -3.23% | -1.58K |
$15.98 | -$25,208.55 | 47.31K |
May 14
| |||
Form 4
| +18.87% | 7.76K |
—
|
—
| 48.89K |
May 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 1
| |||
Form 4
| +7.90% | 3.01K |
$15.13 | -$49,678.71 | 41.13K |
May 15 - May 16
| |||
Form 4
| -54.12% | -44.96K |
$14.95 | -$672,181.90 | 38.12K |
May 5
| |||
Form 4
|
—
|
0
|
$10.03 | -$59,175.00 | 83.08K |
Scheduled
|
Mar 2
| ||
Form 4
| -10.74% | -10.00K |
$10.06 | -$100,600.00 | 83.08K |
Scheduled
|
Feb 9
| ||
Form 4
|
—
|
0
|
$8.53 | -$7,575.00 | 93.08K |
Scheduled
|
Jan 31
| ||
Form 4
| +14.38% | 11.7K |
—
|
—
| 93.08K |
May 17
| |||
Form 4
| -4.88% | -4.18K |
$6.84 | -$28,549.79 | 81.38K |
May 10
| |||
Form 4
| +15.12% | 11.24K |
$5.53 | -$20,156.85 | 85.56K |
May 11 - May 12
| |||
Form 4
| +21.18% | 12.99K |
—
|
—
| 74.32K |
May 22
| |||
Form 4
| -7.42% | -4.91K |
$6.52 | -$32,032.76 | 61.33K |
May 13
| |||
Form 4
| +29.32% | 15.02K |
$4.50 | -$11,170.07 | 66.24K |
May 14 - May 15
| |||
Form 4
| +9.97% | 4.64K |
$11.30 | -$47,551.95 | 51.22K |
Feb 1
| |||
Form 4
| +47.50% | 15K |
—
|
—
| 46.58K |
Feb 1
| |||
Form 4
| -11.76% | -4.21K |
$6.57 | -$27,659.70 | 31.58K |
Jan 25
| |||
Form 4
| +43.16% | 10.79K |
$5.19 | -$21,849.90 | 35.79K |
Jan 23 - Jan 25
| |||
Form 4
| +150.00% | 15K |
—
|
—
| 25K |
Jan 23
| |||
Form 4
|
∞
| 10K |
$4.59 | $45,905.00 | 10K |
Aug 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Larimar Therapeutics, Inc. (LRMR) Snapshot price: $8.05
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +27.72% | 31.25K |
—
|
—
| 144K |
Jan 17
| |||
Form 4
| +4.64% | 5K |
$3.73 | $18,631.50 | 112.75K |
May 17
| |||
Form 4
| +239.40% | 76K |
—
|
—
| 107.75K |
Jan 31
| |||
Form 4
|
∞
| 31.75K |
$3.15 | $99,999.90 | 31.75K |
Sep 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Recro Pharma, Inc. (SCTL) No price found
Chief Operating Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
| +71.27% | 19.08K |
$7.99 | -$14,238.18 | 45.85K |
Jan 18
| |||
Form 4
| +64.58% | 17.29K |
$7.99 | -$14,238.18 | 44.06K |
Jan 18
| |||
Form 4
| -5.98% | -1.70K |
$7.41 | -$12,611.82 | 26.77K |
Jan 2
| |||
Form 4
| +18.18% | 4.38K |
$8.89 | -$17,957.80 | 28.48K |
Jan 18
| |||
Form 4
| +488.40% | 20K |
—
|
—
| 24.09K |
Jan 2
| |||
Form 4
|
∞
| 4.09K |
$9.04 | -$17,221.20 | 4.09K |
Sep 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
KENSEY NASH CORP No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -2.50K |
$38.50 | -$96,250.00 |
0
|
Jun 22
| |||
Form 4
| -72.47% | -6.58K |
$38.50 | -$253,330.00 | 2.5K |
Jun 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 20
| |||
Form 4
| -9.20% | -920.00 |
$22.46 | -$20,663.20 | 9.08K |
Mar 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 22
| |||
Form 4
|
∞
| 10K |
—
|
—
| 10K |
Mar 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||